PI3K/AKT/mTOR信号通路抑制剂在淋巴瘤中的研究进展  

Research progress on PI3K/AKT/mTOR signal pathway in lymphoma

作　　者：刘慧[1] 李鑫[1] 胡腾鹏[1] 孙振昌[1] 张明智[1] 

机构地区：[1]郑州大学第一附属医院肿瘤内科,郑州市450000

出　　处：《中国肿瘤临床》2016年第5期211-215,共5页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金项目(编号:8157010926);河南省科技厅创新人才项目;河南省科技开放合作项目;河南省科技重点项目(编号:340600531502)资助~~

摘　　要：磷脂酰肌醇-3激酶(phosphatidylinositol 3-kinase,PI3K)-蛋白激酶B(protein kinase B,PKB,又称AKT)-雷帕霉素靶蛋白(mammalian target of rapamycin,m TOR)信号通路与细胞的生长、增殖、分化、凋亡、代谢等密切相关,在多种实体肿瘤中已发现该信号通路的异常。近年来,以抑制该通路特定位点的靶向治疗已成为抗肿瘤的研究热点。许多该位点新型抑制剂也已进入淋巴瘤的临床试验中,本文就该通路在淋巴瘤中的活化状态及各个分子靶点抑制剂的研究进展做一综述。The phosphoinositide-3 kinase （PI3K）/protein kinase B （PKB/AKT）/mammalian target of rapamycin （mTOR） pathway is asso- ciated with cell growth, proliferation, differentiation, apoptosis and metabolism. The abnormalities of this signal pathway are found in various malignant tumors. This pathway has also been investigated as an anti-tumor target. Recently, novel inhibitors have been stud- ied in clinical trials of lymphoma. This review summarizes the activation status of the PI3K/AKT/mTOR pathway and its use for targeted therapy of lymphoma.

关 键 词：淋巴 瘤信号转导 PI3K/AKT/mTOR信号通路 靶向治疗 

分 类 号：R733.1[医药卫生—肿瘤]